This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Out of public health concerns and given the current travel restrictions and lab closures worldwide because of COVID-19, the 27th International Symposium on Hepatitis C Virus and Related Viruses (HCV2020), scheduled to take place July 6 – 9, 2020 in Montreal, Canada has been postponed to July 6 - 9, 2021 and will now be delivered Virtually.

HCV2021 Program

VIRTUAL PLATFORM ACCESS

Click Here to access the HCV Virtual Platform.

Reach out to HCVregistration@mci-group.com for any assistance with logging in.


All times are in Eastern Daylight Time (EDT) / (GMT - 4:00)

*Program & Topics/Titles are Subject to Change 

Tuesday, July 6, 2021

  • 10:00 10:15

    Welcome Address

    Naglaa Shoukry

  • 10:15 10:45

    Plenary Lecture 1: Challenges of HCV Elimination

    Jordan Feld University of Toronto, Toronto, ON, Canada

  • 10:45 12:45

    Session 1: Liver Inflammation, Viral Pathogenesis and Carcinogenesis

    Co-Chairs: Robert Thimme & Meital Gal-Tanamy

    10:45 - 11:15 | Plenary Lecture 2: Combination Approaches for the Treatment of NASH and Fibrosis
                               James Trevaskis -
    Gilead, Foster City, CA, USA

    11:15 - 11:45 | Keynote Lecture 1: Mapping the Human Liver using Single Cell RNAseq
                               Sonya MacParland -
    University of Toronto, Toronto, ON, Canada

    11:45 - 12:00 | BREAK

    12:00 - 12:45 | Oral Presentations selected from Abstracts  

    12:00 - 12:15 | Hepatitis C Virus Infection Restricts Human LINE-1 Retrotransposition in Hepatoma Cells
                               Anja Schoebel, Philipps University of Marburg, Germany

    12:15 - 12:30 | HCV NS3/4A protease cleaves SPG20 for formation of large lipid droplets
                               Chieko Matsui, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Japan

    12:30 - 12:45 | Contribution of the Cellular Lipid Kinase PI4KA to HCV-induced Liver Pathogenesis
                               Cong Si Tran, Heidelberg University, Germany

  • 12:45 13:15

    Break

  • 13:15 15:30

    Session 2: Tools for HCV Elimination: Diagnostics, Sequencing and Beyond

    Co-chairs: Jens Bukh & Emma Thomson

    13:15 - 13:45 | Plenary Lecture 3: Advances in HCV Diagnostics and Point of Care Testing
                               Jean-Michel Pawlotsky - National Reference Center for Viral Hepatitis B, C and Delta; Head, Department of Virology, Hôpital, Créteil, France

    13:45 - 14:15 | Keynote Lecture 2: How Realtime Data can Drive HCV Prevention, Care and Treatment: Lessons Learned from Fighting COVID-19
                               Mel Krajden - BC Centre for Disease Control, Vancouver, BC, Canada

    14:15 - 14:45 | Keynote Lecture 3: Tracking HCV Transmission using Next Generation Sequencing
                               Rowena Bull - University of New South Wales, Sydney, Australia

    14:45 - 15:30 | Oral Presentations selected from Abstracts  

    14:45 - 15:00 | Universal vs risk-based screening for prenatal Hepatitis C (HCV): a six-month comparison in Alberta, Canada
                               Alexa Thompson, University of Alberta, Canada

    15:00 - 15:15 | HCV diversity and treatment outcomes following direct-acting antiviral (DAA) therapy in Benin
                               Lucrèce Ahovègbé, Mbarara University of Science and Technology, Uganda

  • 15:30 15:45

    Break

  • 15:45 16:45

    Session 3: SARS‑CoV2 / HCV Interaction

    Co-chairs: Volker Lohmann & Joyce Wilson

    15:45 - 16:15 | Plenary Lecture: Broad spectrum antivirals for Coronavirus infections
                               Daria Hazuda - Vice-President, Infectious Disease and Vaccines, New York, USA

    16:15 - 16:45 | Oral Presentations selected from Abstracts  

    16:15 - 16:30 | SARS-CoV-2 entry is enhanced in HCV pre-infected hepatocytes leading to HCV-SARS-CoV2 co-infection state
                               Tom Domovitz, Bar Ilan University, Israel

    16:30 - 16:45 | Nucleoside-modified mRNA Lipid Nanoparticle Vaccine for HCV
                               Erin K Reagan, University of Pennsylvania, United States

  • 16:45 17:00

    Break

  • 17:00 18:00

    Nobel Prize Celebration

    Co-chairs: Lorne Tyrrell & Naglaa Shoukry

    Harvey Alter
    Michael Houghton
    Charles Rice

  • 18:00 18:45

    Networking

  • 18:45 19:00

    Day One Close